Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
GSK3845097 in advanced Synovial Sarcoma and MRCLS
NCT05943990Phase 1Terminated
- Sponsor
- Adaptimmune Therapeutics
- Start
- Dec 2020
- Primary completion
- Oct 2022
- Modality
- Gene Editing, Gene Silencing, TCR-Engineered T Cells
- Countries
- 6
01
Overview
Phase 1, open-label, single-arm trial of GSK3845097 in synovial sarcoma (SS) and Myxoid Round Cell Liposarcoma (MRCLS), sponsored by Adaptimmune Therapeutics. Primary endpoints: Number of Participants With Dose Limiting Toxicities at 28 days, Number of Participants With Treatment Emergent Adverse Events and Serious AEs at 21 months and 1 more. Started Dec 2020; status: terminated.
02
Drugs
GSK3845097
03
Conditions
synovial sarcoma (SS)Myxoid Round Cell Liposarcoma (MRCLS)
Beyond the preview
Go deeper on NCT05943990.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05943990.